Al Amyloidosis clinical trials

Explore recruiting al amyloidosis clinical trials.

Recruiting al amyloidosis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Al Amyloidosis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

Denmark, Italy, Netherlands, Belgium, Hungary, Germany +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A phase 2, open label, multicenter, single-stage study to evaluate the efficacy of Isatuximab plus Pomalidomide and Dexamethasone (IPd), in patients with AL amyloidosis not in VGPR or better after any previous therapy

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 1/2 Study of Linvoseltamab in Patients with Relapsed or Refractory Systemic Light Chain Amyloidosis

Spain, Greece

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis

Netherlands, Germany, Greece, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis

Belgium, Denmark, Austria, Netherlands, Germany, France +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

An open-label, multi-center, non-randomized pivotal Phase 3 study to evaluate the efficacy and safety of [18F]florbetaben Positron Emission Tomography (PET) imaging to diagnose cardiac AL amyloidosis

Spain, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

Al Amyloidosis trials by city

Al Amyloidosis in Toronto Al Amyloidosis in Vancouver Al Amyloidosis in Montreal Al Amyloidosis in Calgary Al Amyloidosis in Edmonton Al Amyloidosis in Ottawa Al Amyloidosis in Winnipeg Al Amyloidosis in Quebec City Al Amyloidosis in Hamilton Al Amyloidosis in Kitchener Al Amyloidosis in London Al Amyloidosis in Halifax Al Amyloidosis in New York Al Amyloidosis in Los Angeles Al Amyloidosis in Chicago Al Amyloidosis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease